Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc. (VYGR): 12 pipeline candidates · ~13 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
12.6 months
D/E 0.26 · 0% dilution
Lead: Preclinical
12 candidates
N/A
0 buys · 11 sells (180d)
A transparent, data-derived signal for Voyager Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$219.6M
Cash
$46.0M
Quarterly Burn
$33.4M
Runway
12.6 mo
Revenue
$2.6M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| gba1 gene replacement | Preclinical |
| gba1 gene therapy | Preclinical |
| nbib-'223 | Preclinical |
| novartis hd program | Preclinical |
| novartis hd program product | Preclinical |
| sod1 silencing gene therapy | Preclinical |
| tau silencing gene therapy | Preclinical |
| vectorized anti-amyloid antibody | Preclinical |
| vy-fxn01 | Preclinical |
| vy-tau01 | Preclinical |
Showing 10 of 12 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
131
Total value held
$117.7M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 5,568,381 | $21.5M |
| vanguard capital management llc | 4,566,506 | $17.6M |
| armistice capital, llc | 3,500,000 | $13.5M |
| millennium management llc | 3,428,571 | $13.2M |
| geode capital management, llc | 1,049,978 | $4.1M |
| state street corp | 948,226 | $3.7M |
| dimensional fund advisors lp | 875,568 | $3.4M |
| vanguard portfolio management llc | 725,769 | $2.8M |
| morgan stanley | 681,711 | $2.6M |
| two sigma investments, lp | 615,660 | $2.4M |
Showing top 10 of 131 institutional holders of Voyager Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Voyager Therapeutics, Inc.'s pipeline?
Voyager Therapeutics, Inc. (VYGR) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Voyager Therapeutics, Inc.'s lead drug candidate?
Voyager Therapeutics, Inc.'s most advanced tracked candidate is gba1 gene replacement (Preclinical) for Parkinson's disease.
What is Voyager Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Voyager Therapeutics, Inc. has approximately 12.6 months of cash runway.
What is Voyager Therapeutics, Inc.'s market capitalization?
Voyager Therapeutics, Inc.'s market capitalization is approximately $219.6M.
Who is the CEO of Voyager Therapeutics, Inc.?
Dr. Alfred W. Sandrock Jr., M.D., Ph.D. is the chief executive officer of Voyager Therapeutics, Inc. (VYGR).
Get the full picture on Voyager Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.